BACKGROUND: Inflammation and chronic kidney disease (CKD) are both associated with cardiovascular disease (CVD). Whether inflammatory biomarkers are associated with kidney function and albuminuria after accounting for traditional CVD risk factors is not completely understood. METHODS: The sample comprised Framingham Offspring cohort participants (n = 3294, mean age 61, 53% women) who attended the seventh examination cycle (1998-2001). Inflammatory biomarkers [C-reactive protein (CRP), tumour necrosis factor (TNF)-alpha, interleukin-6, TNF receptor 2 (TNFR2), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), P-selectin, CD-40 ligand, osteoprotegerin, urinary isoprostanes, myeloperoxidase and fibrinogen] were measured on fasting blood samples. Serum creatinine-based estimated glomerular filtration rate (eGFR) and serum cystatin C concentration were used to assess kidney function. Urinary albumin-to-creatinine ratio (UACR) was used to assess albuminuria. Linear or logistic regression was used to test associations between biomarkers and kidney measures. RESULTS: Chronic kidney disease (CKD), defined as eGFR < 59/64 mL/min/1.73 m(2) in women/men, was present in 8.8% (n = 291) of participants. TNF-alpha, interleukin-6, TNFR2, MCP-1, osteoprotegerin, myeloperoxidase and fibrinogen were higher among individuals with CKD; all biomarkers except for urinary isoprostanes were elevated in higher cystatin C quartiles; and TNF-alpha, interleukin-6, TNFR2, ICAM-1 and osteoprotegerin were elevated in higher UACR quartiles-all assessed after multivariable adjustment. Almost 6% and 17% of variability in TNFR2 were explained by CKD status and higher cystatin C quartiles, respectively. CONCLUSIONS: Biomarkers of inflammation are associated with kidney function and albuminuria. In particular, substantial variability in soluble TNFR2 is explained by CKD and cystatin C.
BACKGROUND:Inflammation and chronic kidney disease (CKD) are both associated with cardiovascular disease (CVD). Whether inflammatory biomarkers are associated with kidney function and albuminuria after accounting for traditional CVD risk factors is not completely understood. METHODS: The sample comprised Framingham Offspring cohort participants (n = 3294, mean age 61, 53% women) who attended the seventh examination cycle (1998-2001). Inflammatory biomarkers [C-reactive protein (CRP), tumour necrosis factor (TNF)-alpha, interleukin-6, TNF receptor 2 (TNFR2), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), P-selectin, CD-40 ligand, osteoprotegerin, urinary isoprostanes, myeloperoxidase and fibrinogen] were measured on fasting blood samples. Serum creatinine-based estimated glomerular filtration rate (eGFR) and serum cystatin C concentration were used to assess kidney function. Urinary albumin-to-creatinine ratio (UACR) was used to assess albuminuria. Linear or logistic regression was used to test associations between biomarkers and kidney measures. RESULTS:Chronic kidney disease (CKD), defined as eGFR < 59/64 mL/min/1.73 m(2) in women/men, was present in 8.8% (n = 291) of participants. TNF-alpha, interleukin-6, TNFR2, MCP-1, osteoprotegerin, myeloperoxidase and fibrinogen were higher among individuals with CKD; all biomarkers except for urinary isoprostanes were elevated in higher cystatin C quartiles; and TNF-alpha, interleukin-6, TNFR2, ICAM-1 and osteoprotegerin were elevated in higher UACR quartiles-all assessed after multivariable adjustment. Almost 6% and 17% of variability in TNFR2 were explained by CKD status and higher cystatin C quartiles, respectively. CONCLUSIONS: Biomarkers of inflammation are associated with kidney function and albuminuria. In particular, substantial variability in soluble TNFR2 is explained by CKD and cystatin C.
Authors: Mark J Sarnak; Anthony Poindexter; Shin-Ru Wang; Gerald J Beck; John W Kusek; Santica M Marcovina; Tom Greene; Andrew S Levey Journal: Kidney Int Date: 2002-12 Impact factor: 10.612
Authors: Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Michael G Shlipak; Linda F Fried; Casey Crump; Anthony J Bleyer; Teri A Manolio; Russell P Tracy; Curt D Furberg; Bruce M Psaty Journal: Circulation Date: 2003-01-07 Impact factor: 29.690
Authors: T A Ikizler; J D Morrow; L J Roberts; J A Evanson; B Becker; R M Hakim; Y Shyr; J Himmelfarb Journal: Clin Nephrol Date: 2002-09 Impact factor: 0.975
Authors: Victoria Cachofeiro; Marian Goicochea; Soledad García de Vinuesa; Pilar Oubiña; Vicente Lahera; José Luño Journal: Kidney Int Suppl Date: 2008-12 Impact factor: 10.545
Authors: Carmen A Peralta; Ronit Katz; Michael Shlipak; Ruth Dubin; Ian DeBoer; Nancy Jenny; Annette Fitzpatrick; Carol Koro; Bryan Kestenbaum; Joachim Ix; Mark Sarnak; Mary Cushman Journal: Am J Nephrol Date: 2011-11-01 Impact factor: 3.754
Authors: L Parker Gregg; Maria Clarissa Tio; Xilong Li; Beverley Adams-Huet; James A de Lemos; S Susan Hedayati Journal: Am J Nephrol Date: 2018-06-06 Impact factor: 3.754
Authors: Meredith C Foster; Nimrta Ghuman; Shih-Jen Hwang; Joanne M Murabito; Caroline S Fox Journal: Am J Kidney Dis Date: 2012-08-15 Impact factor: 8.860
Authors: Richard L Amdur; Harold I Feldman; Jayanta Gupta; Wei Yang; Peter Kanetsky; Michael Shlipak; Mahboob Rahman; James P Lash; Raymond R Townsend; Akinlolu Ojo; Akshay Roy-Chaudhury; Alan S Go; Marshall Joffe; Jiang He; Vaidyanathapuram S Balakrishnan; Paul L Kimmel; John W Kusek; Dominic S Raj Journal: Clin J Am Soc Nephrol Date: 2016-06-23 Impact factor: 8.237
Authors: Axel C Carlsson; Tobias E Larsson; Johanna Helmersson-Karlqvist; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121